Fremanezumab for the Prevention of Menstrually-related Migraine Attacks

NCT06659120 · clinicaltrials.gov ↗

RECRUITING

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Menstrual Migraine

Interventions

DRUG: Fremanezumab

Sponsor

Insel Gruppe AG, University Hospital Bern